Invitrogen Corporation and BioTek Instruments Announce Strategic Collaboration
News Jul 17, 2008
Invitrogen Corporation and BioTek Instruments, Inc. have entered into a collaboration agreement to validate the compatibility of Invitrogen’s reagents and technology platforms with BioTek’s microplate detection instruments.
Invitrogen’s drug discovery products used to study key target classes have been validated on BioTek’s Synergy™ 4 Multi-Mode Microplate Reader with Hybrid Technology™. This includes:
• GeneBLAzer® FRET cell-based technology for signal transduction pathways and G protein-coupled receptors,
• LanthaScreen™ TR-FRET technology for kinases and nuclear hormone receptors,
• Adapta™ Universal Kinase Assay, a new TR-FRET assay system for lipid kinases,
• Z’-LYTE® assay for kinase profiling,
• Omnia® assay for measuring real-time kinase activity.
Additionally, BioTek’s Synergy 4 and Synergy 2 Multi-Mode Microplate Readers have received the LanthaScreen™ Certified+ designation from Invitrogen. Through this collaboration, BioTek and Invitrogen will continue to develop and promote joint applications for the drug discovery market.
“Through this partnership, drug discovery researchers will be able to obtain integrated instrumentation and reagent solutions, thereby removing the frustration of discovering that the biological assay system they have chosen is not compatible with the instrumentation and vice versa,” said John Printen, director of Invitrogen’s Cell Signaling business segment.
“The pharmaceutical research scientist is increasingly under pressure to complete projects faster and this partnership is designed to save the customer valuable time and resources.”
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
Rapid Test Helps with Administering the "Correct" DrugNews
In just three hours, a new rapid test will give information on which available antibiotic is still effective in a concrete case.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018